ALB and fatty liver disease: Emerging research expanding on the relationship between the systemic immune-inflammation index (SII) and nonneoplastic diseases has illustrated its association with increased urinary albumin excretion (17) and hepatic steatosis (18), advocating for its adoption as a novel biomarker for cardiovascular risk factors (19).